Jefferies downgraded Lava Therapeutics (LVTX) to Hold from Buy with a price target of $1.50, down from $3, after the company entered into an agreement to be acquired by XOMA Royalty (XOMA) for between $1.16 and $1.24 per share in cash.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LVTX: